The U.S. Food and Drug Administration (FDA) approved opioid pain medicine safety labeling changes designed to help healthcare professionals and patients better understand the risks associated with opioid analgesics.

The class-wide labeling updates apply to opioid pain medicines, including immediate-release (IR) and extended-release (ER) or long-acting (LA) formulations.

The FDA originally outlined the proposed safety changes in a Drug Safety Communication issued in April 2023. The final labeling updates emphasize the relationship between opioid dosage and overdose risk, appropriate duration of opioid therapy, appropriate use of ER/LA opioid medicines, and the potential for opioid-induced hyperalgesia (OIH).

These changes are part of the FDA's broader efforts to promote safer opioid prescribing and reduce the risks of misuse, overdose, and opioid-related deaths.

What Are the New Opioid Labeling Changes?

The FDA's opioid pain medicine safety updates provide additional information intended to support safer prescribing and use of opioid analgesics.

The updated labeling emphasizes several important principles:

• The risk of overdose increases as the opioid dosage increases.

• Immediate-release opioids should not be used for an extended period unless the patient's pain remains severe enough to require opioid treatment and alternative options remain inadequate.

• Many acute pain conditions treated in outpatient settings require no more than a few days of opioid pain medicine.

• Extended-release and long-acting opioid medicines should generally be reserved for severe and persistent pain that requires extended treatment with a daily opioid analgesic when alternative treatment options are inadequate.

• The labeling includes a warning about opioid-induced hyperalgesia.

• Healthcare professionals are provided with information to help distinguish opioid-induced hyperalgesia from opioid tolerance and withdrawal.

The changes are intended to provide clearer safety information without suggesting that opioid analgesics should never be used.

Why Did the FDA Update Opioid Labels?

Opioid analgesics can provide important pain relief for appropriate patients, but they also carry significant risks.

The FDA has therefore sought to improve the information available to healthcare professionals when opioids are prescribed.

The updated labeling recognizes the importance of balancing two considerations:

Patients with appropriate medical indications should have access to effective pain management, while the risks associated with opioid therapy should be carefully considered and managed.

The FDA stated that the labeling changes were intended to help ensure that patients and prescribers understand both the benefits and risks of opioid pain medicines.

Opioid Dosage and Overdose Risk

One of the key additions to the updated labeling is language emphasizing that the risk of overdose increases as the opioid dosage increases.

This is an important consideration when initiating or adjusting opioid therapy.

Higher opioid exposure can increase the risk of serious adverse effects, including respiratory depression and overdose.

Healthcare professionals should therefore consider the patient's individual circumstances, pain severity, previous opioid exposure, other medications, and relevant risk factors when determining an appropriate treatment plan.

Patients should also take opioid medicines exactly as prescribed and should not independently increase the dose because their pain has not improved.

Appropriate Duration of Immediate-Release Opioids

The FDA's labeling changes also address the duration of treatment with immediate-release (IR) opioids.

The updated information states that IR opioids should not be used for an extended period unless:

1. The patient's pain remains severe enough to require opioid treatment, and

2. Alternative treatment options continue to be inadequate.

The FDA also emphasized that many acute pain conditions managed in outpatient settings require no more than a few days of opioid pain medicine.

This does not mean that every patient should receive opioids for the same number of days.

The appropriate duration depends on the underlying condition, severity of pain, response to treatment, and the clinical judgment of the healthcare professional.

When Should ER/LA Opioids Be Used?

The labeling changes also provide additional guidance regarding extended-release (ER) and long-acting (LA) opioid medicines.

The FDA recommends reserving these formulations for severe and persistent pain that requires an extended treatment period with a daily opioid analgesic when alternative treatment options are inadequate.

ER/LA opioids are designed to provide opioid exposure over a longer period than immediate-release formulations.

Because of their pharmacologic characteristics and associated risks, healthcare professionals need to carefully assess whether an ER/LA opioid is appropriate for an individual patient.

The decision should consider the patient's pain condition, treatment history, response to previous therapies, and potential risks associated with opioid therapy.

What Is Opioid-Induced Hyperalgesia?

Another important part of the FDA's opioid pain medicine safety labeling update is the addition of information about opioid-induced hyperalgesia (OIH).

Opioid-induced hyperalgesia is a condition in which exposure to opioids can be associated with an increased sensitivity to pain.

In other words, rather than simply relieving pain, opioid exposure can, in some circumstances, contribute to increased pain sensitivity.

This can make clinical assessment challenging because worsening pain in a patient receiving opioids does not necessarily mean that the underlying disease has become worse or that a higher opioid dose is automatically appropriate.

The updated labeling therefore draws attention to the need for healthcare professionals to consider OIH when evaluating patients whose pain changes during opioid treatment.

OIH vs Opioid Tolerance and Withdrawal

An important part of the FDA's update is information intended to help healthcare professionals distinguish opioid-induced hyperalgesia from opioid tolerance and withdrawal.

These conditions can have overlapping features but are not the same.

Opioid-induced hyperalgesia

OIH involves increased sensitivity to pain associated with opioid exposure.

Opioid tolerance

Tolerance occurs when repeated exposure to a drug results in a reduced response to the same dose, meaning that a higher dose may be required to produce the same effect.

Opioid withdrawal

Withdrawal can occur when a person who has developed physical dependence on an opioid reduces or stops opioid use.

Withdrawal can produce a characteristic group of symptoms and requires appropriate clinical management.

Because these conditions can be difficult to distinguish in practice, healthcare professionals should evaluate the individual patient's symptoms, medication history, treatment response, and overall clinical condition rather than assuming that worsening pain automatically means the opioid dose should be increased.

What the Changes Mean for Healthcare Professionals

The updated FDA labeling provides additional information that healthcare professionals can consider when prescribing and monitoring opioid analgesics.

Prescribers should carefully evaluate:

• The severity and cause of pain

• Whether opioid treatment is appropriate

• Available non-opioid and non-pharmacologic options

• The patient's previous opioid exposure

• The intended duration of therapy

• The selected opioid formulation

• The patient's risk factors for opioid-related harm

• Potential drug interactions and concurrent central nervous system depressants

• Changes in pain during treatment

Pharmacists also play an important role in opioid safety.

They can help identify potential medication-related problems, counsel patients on appropriate opioid use, reinforce prescribed dosing instructions, and communicate with prescribers when concerns arise.

FDA's Overdose Prevention Framework

The labeling changes form part of the FDA's broader Overdose Prevention Framework.

The framework represents the agency's approach to developing and implementing actions intended to prevent drug overdoses and reduce overdose-related deaths.

The FDA's opioid labeling update demonstrates how regulatory agencies can use prescribing information to communicate important safety information to healthcare professionals and patients.

Labeling alone, however, is only one component of a broader approach to opioid safety.

Safe prescribing, appropriate dispensing, patient education, monitoring, access to treatment for substance use disorders, and evidence-based overdose prevention strategies are all important components of addressing opioid-related harm.

Why Opioid Safety Matters

Opioid medicines remain important tools for managing certain types of pain.

However, their use requires careful consideration because opioid-related adverse effects can be serious.

The goal of opioid safety is therefore not simply to eliminate opioid prescribing.

Instead, the goal is to ensure that opioids are used appropriately, safely, and when the expected benefits outweigh the potential risks.

The FDA's updated labeling provides healthcare professionals with additional information to support this approach.

Conclusion

The FDA's approval of class-wide opioid pain medicine safety labeling changes represents another step toward safer opioid use.

The updates emphasize that overdose risk increases with higher opioid doses, reinforce the importance of limiting the duration of immediate-release opioid therapy when appropriate, and recommend reserving ER/LA opioid medicines for severe and persistent pain requiring extended opioid treatment when alternative options are inadequate.

The new labeling also highlights opioid-induced hyperalgesia and provides information to help healthcare professionals distinguish it from opioid tolerance and withdrawal.

For pharmacists, prescribers, and other healthcare professionals, understanding these changes can support safer opioid prescribing, dispensing, monitoring, and patient counseling.

Most importantly, opioid therapy should always be individualized. Patients should follow their prescribed treatment plan and discuss concerns about pain, side effects, dose changes, or withdrawal with their healthcare professional rather than making medication changes on their own.

Pharm Tech Important Link Bank:

Here are a few helpful resources to support your pharmacy technician career:

🔗 Free CEUs for Pharmacy Technicians
https://www.pharmtechsonly.com/resource-center/free-ceus/

🔗 Search Upcoming Conventions in Your Area
https://www.pharmtechsonly.com/resource-center/conventions/

🔗 Rx Study Buddy Kit (Top 200, Math, Law)
https://www.pharmtechsonly.com/store/

🔗 Search Pharmacy Technician Jobs
https://tc.pharmtechsonly.com/careers